TargED Eyes 2024 Clinic Entry For Clot Buster On Back Of Financing
€39m Raised In Series A
The Dutch firm expects the financing to advance its novel asset Microlyse into a potentially pivotal study for a rare blood disorder.
You may also be interested in...
Emerging Company Profile: The private German biotech Ariceum has just launched with a €25m financing to advance its lead radioligand candidate, satoreotide, into Phase I development and hopes its antagonist approach could give Novartis’s Lutathera a run for its money.
The US firm released promising interim data from a mid-stage Becker muscular dystrophy trial, claiming success here could translate to Duchenne as it unveiled plans for more studies across similar conditions.
Pfizer will invest in partner Valneva’s late-stage Lyme disease jab program, providing much-needed financial support to the French firm which has suffered COVID-19 vaccine sales setbacks.